RepliCel Now Accepting Applications for Upcoming Clinical Trials of Hair Cloning Technology

RepliCel™ Life Sciences, based in Vancouver, British Columbia, is currently accepting the names of people interested in maybe participating in the next round of its clinical trials of its new hair cloning treatment. Its current Phase I/IIa clinical trials, being conducted in Georgia, are scheduled to end in April 2012.

Replical’s hair regeneration technology involves the harvesting and multiplication of what are called dermal sheath cup (DSC) cells located in a “bulb” at the base of the hair follicle.

In laboratory studies, RepliCel™ scientists have found that DSC cells both stimulate the development of mature hair follicles and the creation of new ones. The scientists discovered that the DSC cells are capable of actually regrowing the dermal papilla and hair follicles themselves.

The way the treatment works is this. Trained technicians harvest DSC cells at locations in the base of the neck, where they are plentiful. These harvested DSC cells are then placed in a special nutrient medium in a laboratory where they multiply.

Once there are a sufficient number of DSC cells taken from a patient’s own neck hairs, the new cells are injected directly into the scalp where hair loss has occurred. Like reseeding a lawn, the DSC cells “migrate” to hair papilla that already exist and effect an regenerative transformation. They also create brand-new hair follicles.

Most importantly, the harvested DSC cells are taken from hair follicles, at the base of the head near the neck, that are not as sensitive to male sex hormones (androgens) which, scientists believe, are what cause the hair follicle miniaturization that makes hair loss happen in the first place.

Also, because the DSC cells come from the patient’s own body, rejection of the cells is far less likely.

RepliCel™ is now accepting queries from individuals who might be interested in participating in its new round of clinical trials. If you’d like more information about possibly participating in its new Phase I/IIa clinical trial of its hair regeneration technology, fill in the form below: